What Anteis does

Anteis SA, operating as Merz Aesthetics Anteis SA, is a Swiss biomedical company specializing in the development and manufacturing of injectable medical devices based on biopolymer transformation. Founded in 2003 and headquartered between Plan-les-Ouates (legal seat and FDA-certified site) and Lonay (main operational site, producing 80% of output) in Switzerland, the company operates as a wholly-owned subsidiary of Merz Aesthetics within the broader Merz Group. Its core technology centers on resorbable hyaluronic acid-based dermal fillers, commercialized under the registered Belotero® brand across a seven-product portfolio spanning skin rehydration (Revive), fine line correction (Soft), moderate wrinkles and lip contour (Balance), deep wrinkles (Intense), facial volume restoration (Volume), lip contour (Lips Contour), and lip volumization (Lips Shape), with select products available with or without lidocaine for patient comfort.

The company sells Belotero® products directly to healthcare professionals and aesthetic clinics through enterprise field sales channels, leveraging the parent Merz Aesthetics' global commercial organization to reach practitioners in over 90 countries across five continents. Its revenue model is one-time medical device sales to clinical end-users, with pricing not publicly disclosed. Customer segments are concentrated in medical aesthetics practitioners performing wrinkle correction, lip enhancement, skin rehydration, and facial contouring procedures.

Competitive positioning is supported by proprietary biopolymer transformation know-how, FDA-certified manufacturing, Swiss regulatory compliance, the Belotero® trademark, and Merz Group's century-long heritage in aesthetics. The entity is privately held with no external funding, no disclosed M&A activity, and no independent revenue disclosure, operating as an integrated strategic unit within the Merz Aesthetics corporate structure.

Name

Anteis

Legal name

Anteis SA

Website

https://anteis.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Anteis SA is a Swiss biomedical company and wholly-owned subsidiary of Merz Aesthetics that develops and manufactures the Belotero® line of resorbable hyaluronic acid-based dermal fillers, sold to healthcare professionals and aesthetic clinics in over 90 countries.

Ownership category

akta.pro rank

Product category

Aesthetic Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

akta.pro secondary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

Keywords

• Hyaluronic acid fillers
• Dermal filler products
• Medical aesthetic devices
• Injectable biopolymers
• Resorbable implants

Headquarters

HQ city

Meyrin

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Belotero® Product Sales: Sale of hyaluronic acid-based dermal filler products (Belotero® product line) to healthcare professionals and aesthetic clinics globally.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

Anteis SA develops and manufactures injectable medical devices based on biopolymer transformation, centered on the Belotero® range of resorbable hyaluronic acid-based dermal fillers. The portfolio of seven products addresses wrinkle correction, skin rehydration, lip contouring and shaping, and facial volume restoration, distributed to healthcare professionals and aesthetic clinics in over 90 countries across five continents.

Product overview

Merz Aesthetics®, Anteis SA is a Swiss biomedical company specializing in the development and manufacturing of injectable medical devices based on biopolymer transformation. The company's product portfolio centers on the Belotero® line of hyaluronic acid-based dermal fillers, which includes seven distinct products: Belotero® Revive (skin rehydration), Belotero® Soft (fine lines), Belotero® Balance (moderate wrinkles and lip contour), Belotero® Intense (deep wrinkles), Belotero® Volume (facial volume restoration), Belotero® Lips Contour (lip contour restoration), and Belotero® Lips Shape (lip volumization). All products in the Belotero® range are resorbable fillers that can be used individually or in combination to provide personalized aesthetic solutions. The products are available with or without lidocaine for patient comfort. The Belotero® portfolio is distributed in over 90 countries across five continents.

Differentiator

Problem solved

Functional benefit

Brands

• Belotero®: Extended portfolio of advanced dermal fillers including Revive, Soft, Balance, Intense, Volume, Lips Contour, and Lips Shape products for aesthetic treatments.

Products and services

• Belotero® Revive

Quantifiable outcome

• Products available in 90+ countries across five continents

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Swiss Aesthetic ClinicminorStrategic or Co-development PartnerPartnership with a renowned Swiss aesthetic clinic enabling all employees to receive annual Belotero® injection treatments of the company's flagship product.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Hugel: South Korean aesthetics company with a growing HA filler portfolio (e.g., The Chaeum® line) plus botulinum toxin. Comparable to Belotero® as an HA filler specialist, primarily serving Asia but expanding internationally.

Direct peers

• Revance Therapeutics: US-listed aesthetics company marketing the RHA® Collection of HA dermal fillers (acquired from Teoxane) along with neuromodulators. Directly competes with Belotero® in the resilient HA filler category with similar practitioner-channel distribution.
• Allergan Aesthetics (AbbVie): Aesthetics division of AbbVie and maker of the Juvéderm® family of HA dermal fillers, Belotero®'s most direct global competitor in injectable facial aesthetics. Operates at significantly larger scale with a comparable product portfolio targeting the same clinician and patient base.
• Croma-Pharma: Austrian aesthetics company with a portfolio of HA-based dermal fillers (saypha®) and biostimulators, competing head-to-head with Belotero® in the practitioner-administered HA filler market across Europe and select international markets.
• Sinclair Pharma (Huadong Medicine): Aesthetics-focused company marketing HA dermal fillers (e.g., MaiLi®, Perfectha®) and complementary biostimulators, serving the same aesthetic clinic channel as Belotero® with a comparable HA product line.
• Galderma: Global dermatology pure-play and maker of the Restylane® HA filler portfolio alongside Sculptra® and other aesthetic injectables. Direct competitor to Belotero® in HA dermal fillers with a comparable global commercial footprint.
• Teoxane: Swiss-based HA dermal filler specialist (Teosyal®/Teoxane RHA® range), directly comparable to Anteis as a Geneva-area competitor in resorbable HA injectables serving the same aesthetic practitioner channel.
• Prollenium Medical Technologies: Canadian manufacturer of HA dermal fillers (Revanesse® line) and other injectable aesthetics. Direct competitor to Belotero® in resorbable HA fillers with growing global distribution in the same clinic channel.

Emerging players

• Evolus: Aesthetic medicine company known for the Jeuveau® neuromodulator, now expanding into HA dermal fillers and adjacent aesthetics categories. A newer competitor to Belotero® in the practitioner aesthetics channel, with a still-narrower product range.

Broad incumbents

• Merz Aesthetics (Merz Group): Parent organization of Anteis and a broad aesthetics incumbent with a portfolio spanning HA fillers (Belotero® via Anteis), botulinum toxin (Xeomin®/Bocouture®), and biostimulators. The relevant comparable at the parent-portfolio level, even though Belotero® itself is the anchor's product.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anteis